Browsing by Subject "fibroblast growth factor receptor"

Now showing 1 - 2 of 2
  • Thumbnail Image
    Item
    Papillomavirus E2 protein is regulated by specific fibroblast growth factor receptors
    (Elsevier, 2018-08) DeSmet, Marsha; Kanginakudru, Sriramana; Jose, Leny; Xie, Fang; Gilson, Timra; Androphy, Elliot J.; Dermatology, School of Medicine
    The papillomavirus (PV) E2 protein activates transcription and replication by recruiting cellular proteins and the E1 DNA helicase to their binding sites in the viral genome. We recently demonstrated that phosphorylation of tyrosine 102 in the bovine papillomavirus (BPV-1) E2 protein restricts these activities and that fibroblast growth factor receptor-3 (FGFR3) tyrosine kinase binds PV E2. Expression of FGFR3 decreased viral replication with both wild-type and the phenylalanine substitution at position 102, inferring that another kinase targets Y102. Here we tested FGFR- 1, −2 and −4 for association with PV E2 proteins. FGFR2 but not FGFR1 or FGFR4 co-immunoprecipitated with BPV-1 E2. We found that FGFR2 suppressed replication but did not depend on phosphorylation of BPV-1 Y102. HPV-16 and −31 E2 interacted with FGFR1, −2, and −4. These results imply that the expression and activity of FGF receptors in epithelial cells can regulate the function of E2 in viral replication.
  • Thumbnail Image
    Item
    Targeting fibroblast growth factor receptor (FGFR) pathway in renal cell carcinoma
    (Taylor and Francis, 2015) Massari, Francesco; Ciccarese, Chiara; Santoni, Matteo; Lopez-Beltran, Antonio; Scarpelli, Marina; Montironi, Rodolfo; Cheng, Liang; Department of Pathology and Laboratory Medicine, IU School of Medicine
    Fibroblast growth factor receptor (FGFR) pathway is involved in driving vascular endothelial growth factor (VEGF)-independent tumor angiogenesis, as a compensatory mechanism to escape VEGF-targeted therapies. Therefore, targeting FGF/FGFR axis seems to be a promising strategy in order to inhibit tumor angiogenesis and reduce resistance to VEGF receptor-tyrosine kinase inhibitors. This editorial is focused on the role of FGF/FGFR pathway in renal cell carcinoma and on the ongoing trials of emerging agents targeting this axis.